Platelet transfusion thresholds for thrombocytopenic infants

Area of Science:

• Neonatal Medicine
• Hematology
• Evidence-Based Medicine

Background:

• Neonatal thrombocytopenia is commonly treated with platelet transfusions, but transfusion thresholds vary widely.
• Existing thresholds for stable, non-bleeding neonates range from 25,000 to 150,000 platelets/microliter.

Purpose of the Study:

• To evaluate the benefits and harms of restrictive versus liberal platelet transfusion thresholds in neonates with thrombocytopenia.
• To synthesize evidence from randomized controlled trials on neonatal platelet transfusion practices.

Main Methods:

• Searched multiple databases (CENTRAL, MEDLINE, Embase) and trial registries up to June 2025.
• Included RCTs, quasi-RCTs, and cluster-RCTs comparing different platelet transfusion thresholds in thrombocytopenic neonates.
• Analyzed outcomes including death, major bleeding, any hemorrhage, and neurodevelopmental impairment.

Main Results:

• Restrictive thresholds significantly reduced the number of platelet transfusions in mild and severe thrombocytopenia ranges.
• No clear evidence of benefit for higher transfusion thresholds regarding death or bleeding was found.
• Evidence for outcomes like death and major bleeding was of very low to low certainty, with some comparisons lacking precision.

Conclusions:

• Lower platelet transfusion thresholds likely decrease transfusions without increasing the risk of death or major bleeding.
• The current evidence is of moderate to very low certainty, indicating a need for more high-quality research.
• Higher transfusion thresholds did not demonstrate a benefit for key outcomes in thrombocytopenic neonates.